| Literature DB >> 24348586 |
Fereidoun Azizi1, Parvin Mirmiran1, Amir Abbas Momenan1, Farzad Hadaegh1, Ali Habibi Moeini1, Firoozeh Hosseini1, Saleh Zahediasl1, Arash Ghanbarian1, Farhad Hosseinpanah1.
Abstract
BACKGROUND: It has been shown that life style modification may decrease the prevalence of metabolic syndrome, but this intervention has not been reported in community setting.Entities:
Keywords: Community-Based; Lifestyle; Metabolic Syndrome; Prevalence
Year: 2013 PMID: 24348586 PMCID: PMC3860109 DOI: 10.5812/ijem.5443
Source DB: PubMed Journal: Int J Endocrinol Metab ISSN: 1726-913X
Prevalence of Metabolic Syndrome in Various Age Groups of the Intervention (n = 2961) and Control Groups (n = 3909) at Baseline and After 3.6 Years: Tehran Lipid and Glucose Study
| Age Group, y | Baseline | After 3.6 Years | P value for Change | ||||||
|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
| ||
|
| 10.1 | 11.8 | 0.33 | 13.2 | 0.096 | 13.9 | 0.165 | 0.86 | 0.158 |
|
| 24.7 | 22.4 | 0.87 | 28.5 | 0.08 | 32.5 | < 0.001 | 0.06 | < 0.001 |
|
| 44.1 | 46.1 | 0.68 | 48.4 | 0.053 | 3.6 | < 0.001 | 0.08 | < 0.014 |
|
| 57.8 | 57.1 | 0. 90 | 62.0 | 0.089 | 63.5 | < 0.001 | 0.46 | < 0.069 |
|
| 57.3 | 60.3 | 0.54 | 58.8 | 0.672 | 64.8 | < 0.047 | 0.12 | < 0.009 |
|
| 45.6 | 51.5 | 0.98 | 47.4 | 1.00 | 63.3 | < 0.035 | 0.13 | < 0.001 |
aAdjusted for age and sex.
bAdjusted for age, sex, and baseline value.
cAbbreviations: Int, Intervention; cont, Control
Baseline Characteristics of the Intervention and Control Groups
| Characteristic | Control (n=3909) | Intervention (n=2961) | |
|---|---|---|---|
|
| 40.9 | 40.7 | |
|
| 90.4 | 90.6 | |
|
| 43.3 ± 13.9 [ | 43.8 ± 14.1 | |
|
| 83.1 | 82.5 | |
|
| 11 | 9 | |
|
| 27.1 ± 4.6 | 27.1 ± 4.6 | |
|
| 88.7 ± 12.1 | 88.9 ± 12.1 | |
|
| 0.87 ± 0.08 | 0.87 ± 0.08 | |
|
| 120 ± 19 | 120 ± 19 | |
|
| 78 ± 10 | 78 ± 11 | |
|
| 98.9 ± 34.2 | 99.3 ± 35.3 | |
|
| 7.52 ± 5.64 | 7.08 ± 5.77 | |
|
| 5.5 ± 4.9 | 5.2 ± 4.8 | |
|
| 212 ± 47 | 212 ± 46 | |
|
| 174 ± 121 | 174 ± 120 | |
|
| 135 ± 38 | 136 ± 38 | |
|
| 42.3 ± 10.9 | 42.3 ± 11.0 | |
|
| |||
| Highly active | 26.5 | 23.4 | |
| Moderately active | 18.2 | 16.2 | |
| Mildly active | 30.5 | 34.4 | |
| Not active | 24.8 | 26.0 |
a Except for percentage (%), all numbers are mean ± SD
b Serum insulin concentration, and HOMA-IR were determined in randomly selected 260 and 83 persons of control and intervention groups, respectively.
Prevalence of Metabolic Syndrome and Its Components in the Intervention Group (n = 2961) and Control Group (n=3909) at Baseline and After 3.6 years: Tehran Lipid and Glucose Study
| Baseline | After 3.6 Years | P value for Change | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Int, % [ | Cont[ |
| Int[ |
| Cont |
|
| ||
|
| 37.7 | 38.6 | 0.39 | 41.2 | < 0.001 | 44.7 | < 0.001 | < 0.002 | < 0.001 |
|
| 37.1 | 36.0 | 0.50 | 46.6 | < 0.001 | 48.3 | < 0.001 | < 0.014 | < 0.001 |
|
| 24.6 | 24.3 | 0.89 | 23.7 | 0.28 | 29.0 | <0.001 | < 0.001 | < 0.001 |
|
| 49.8 | 50.3 | 0.58[ | 44.7 | < 0.001 | 47.8 | < 0.002 | 0.014[ | <0.001 |
|
| 69.2 | 69.9 | 0.84[ | 76.1 | < 0.001 | 82.2 | < 0.001 | < 0.001[ | < 0.001 |
|
| 34.6 | 34.2 | 0.94[ | 31.1 | < 0.001 | 29.5 | <0.001 | 0.25[ | < 0.014 |
aAbdominal obesity: waist circumference ≥ 102 cm in men and ≥ 88 cm in women. Elevated fasting glucose: fasting plasma glucose ≥ 5.6 mmol/L. Low HDL cholesterol: HDL cholesterol < 40 mg/dL (< 1.03 mmol) in men and < 50 mg/dL (1.3 mmol/L) in women. Elevated triglycerides: serum fasting triglycerides ≥150 mg/dL (≥1.7 mmol/L). Elevated blood pressure ≥ 130 mmHg, diastolic blood pressure ≥ 85 mmHg, and/or use of antihypertensive medication
bAdjusted for age and sex
cAdjusted for age, sex, and baseline value
dAdjusted for lipid medications.
eAdjusted for blood pressure medications
fAbbreviations: Int, Intervention; Cont; Control
Comparison of Changes in Parameters of Metabolic Syndrome in Various Age Groups of Intervention and Control Subjects After 3.6 Years of Follow up: Tehran Lipid and Glucose Study
| Age Group, y | Change Between Intervention and Control Groupsa,% ( | ||||
|---|---|---|---|---|---|
| Abdominal Obesityb | Hypertensionc | Elevated Fasting Glucose | Elevated Triglyceridesd | Low HDL Cholesterold | |
|
| -0.7 (0.357) | +1.5 (0.071) | -3.5 (< 0.001) | -4.4 (< 0.003) | -3.9 (< 0.029) |
|
| -5.3 (< 0.003) | -1.6 (0.023) | -4.6 (< 0.001) | -3.95 (< 0.001) | -4.5 (< 0.016) |
|
| -1.4 (0.245) | -3.2 (0.256) | -6.8 (< 0.011) | -3.2 (< 0.003) | -6.7 (< 0.001) |
|
| -0.1 (0.48) | +0.8 (0.441) | -10.9 (< 0.001) | -0.6 (0.359) | -11.1 (< 0.001) |
|
| -7.0 (< 0.001) | +7.4 (< 0.001) | -3.2 (< 0.001) | +0.6 (0.39) | -3.2 (< 0.074) |
|
| +1.8 (0.371) | -10.6 (< 0.001) | +1.8 (< 0.001) | -15.03 (< 0.001) | +1.8 (< 0.383) |